| | english | español | français |
Go to record ID

  Home|Finding Information|Record details   Printer-friendly version

Modified Organism
Record information and status
Record ID
Date of creation
2013-10-14 16:05 UTC (gutemberg.sousa@mctic.gov.br)
Date of publication
2013-10-28 20:47 UTC (dina.abdelhakim@cbd.int)

Living Modified Organism identity
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.

LMO name
Transformation event
Dr Leonardo Bruno Ribeiro Costa
President of Biosafety Intern Comission
Intervet do Brasil Veterinária Ltda (INTERVET)
Av. Sir Henry Wellcome 335, Prédio Administrativo, 1º andar, Ala "E", Moinho Velho.
Cotia, São Paulo
Brazil, 06714-050
Phone:55 (11) 4613-4000 / 4613-4006
Fax:55 (11) 4613-4000 / 4613-4006
Innovax®-ND, a recombinant vaccine that helps aid in the protection of Newcastle and Marek's diseases in chickens. Innovax-ND utilizes the herpesvirus of turkey (HVT) to carry Newcastle disease (ND) antigens, which induce immunity against ND.  HVT also protects chickens against Marek's disease, which is caused by a herpesvirus and results in tumors, high mortality and immunosuppression.
Recipient Organism or Parental Organisms
The term Recipient organism refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas Parental organisms refers to those that were involved in cross breeding or cell fusion.
Gallid alphaherpesvirus 2
Point of collection or acquisition of the recipient organism
PB1 strain: non-virulent , non pathogenic strain of the HTV virus, which is used as a vaccine for over two decades.
Characteristics of the transformation process
Techniques used for the modification
  • Homologous Recombination
Introduced or modified genetic elements
Some of these genetic elements may be present as fragments or truncated forms. Please see notes below, where applicable.
Fusion protein gene - Avian orthoavulavirus 1 - Newcastle disease virus, NDV
Production of medical or pharmaceutical compounds (human or animal) - Vaccines
Notes regarding the genetic elements introduced or modified in this LMO
The INNOVAX® ND Vaccine is a recombinant HVT strain that contains a gene that codes for the fusion protein (F-protein) of the Newcastle Disease virus, directed by promoter derived from the Rous sarcoma virus long terminal repeat sequence (LTR).

The gene was integrated into the host genome through homologous recombination as follows:

1. The protein F coding sequence was obtained through cDNA synthesis of genomic NDV, clone 30, RNA that was harvested and purified from infected embryonated eggs.

2. The F-protein coding cDNA was isolated and cloned into the HVT recombination vector  pVECO4, which also contains the Rous sarcoma virus LTR promoter, resulting in the pNDVO4 plasmid.

3. pNDVO4 plasmid DNA and HVT were co-transformed into chicken embryo fibroblasts and incubated under conditions that favour homologous recombination.

4. Selection of the recombinant virus was conducted by immunofluorescence, to detect F protein expression. The resulting strain was named HVT/NDV-F. Sequences of plasmids or markers were not detected in the recombinant virus.
LMO characteristics
Modified traits
Common use(s)
  • Vaccine
Additional Information
Additional Information
With the use of the Innovax ND vaccine, immunity against Newcastle Disease starts at two weeks of age and lasts for at least of 60 weeks after one single dose of the vaccine. For Marek's Disease, immunity starts at the fifth day of age and the vaccine lastes for the whole period of risk.

The vaccine is administered to chicken embryonic eggs at 18 days of incubation through the in ovo route, or to one day chicks through subcutaneous injections.

Records referencing this document (6)
6record(s) found
Country's Decision or any other Communication3 records
Risk Assessment3 records